16:28 EDT Kineta files to sell 890K shares of common stock for holders
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KA:
- Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
- Kineta announces first patient dosed in Phase 1/2 VISTA-101 trial of KVA12123
- Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023